Atrium Therapeutics (RNA) Stock Overview

A biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. More details

RNA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Revenue grew by 70.9% over the past year

Risk Analysis

Earnings are forecast to decline by an average of 23.1% per year for the next 3 years

RNA has negative shareholders equity.

Currently unprofitable and not forecast to become profitable over the next 3 years

RNA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Atrium Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Atrium Therapeutics
Historical stock prices
Current Share Price	US$13.25
52 Week High	US$16.77
52 Week Low	US$11.95
Beta	0
1 Month Change	4.25%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-10.17%

Recent updates

Shareholder Returns

	RNA	US Biotechs	US Market
7D	3.0%	0.1%	2.6%
1Y	n/a	35.5%	26.2%

Return vs Industry: Insufficient data to determine how RNA performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how RNA performed against the US Market.

Price Volatility

Is RNA's price volatile compared to industry and market?
RNA volatility
RNA Average Weekly Movement	7.7%
Biotechs Industry Average Movement	10.7%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

Stable Share Price: RNA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine RNA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2025	n/a	Kathleen Gallagher	atriumtherapeutics.com

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases.

Atrium Therapeutics, Inc. Fundamentals Summary

How do Atrium Therapeutics's earnings and revenue compare to its market cap?
RNA fundamental statistics
Market cap	US$202.78m
Earnings (TTM)	-US$49.50m
Revenue (TTM)	US$18.62m

11.0x

P/S Ratio

-4.2x

P/E Ratio

Is RNA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RNA income statement (TTM)
Revenue	US$18.62m
Cost of Revenue	US$44.27m
Gross Profit	-US$25.65m
Other Expenses	US$23.85m
Earnings	-US$49.50m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-3.19
Gross Margin	-137.76%
Net Profit Margin	-265.88%
Debt/Equity Ratio	0%

How did RNA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/11 18:19
End of Day Share Price	2026/05/11 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atrium Therapeutics, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yanan Zhu	Wells Fargo Securities, LLC

Atrium Therapeutics, Inc.NasdaqGS:RNA Stock Report